Last updated: February 27, 2026
What is ATHROMBIN?
ATHROMBIN (also known by its generic name marchalam or recombinant thrombin) is a topical hemostatic agent used primarily to control bleeding in surgical procedures. It is a recombinant form of human thrombin, approved for specific indications such as bleeding management in cardiovascular, neurosurgical, and orthopedic surgeries.
Market Overview
The global hemostatic agents market was valued at approximately USD 2.2 billion in 2021. It is projected to reach USD 3.4 billion by 2028, growing at a compound annual growth rate (CAGR) of around 6.3% from 2022 to 2028 [1].
Within this market, recombinant thrombin products like ATHROMBIN occupy a niche due to their high purity and safety profile. The recombinant segment is growing faster than blood-derived products, driven by safety concerns over disease transmission and regulatory preferences.
Key Market Drivers
- Increasing surgical procedures worldwide, especially in aging populations.
- Rising prevalence of bleeding disorders and coagulopathies.
- Technological advancements in recombinant protein manufacturing.
- Growing preference for blood-free hemostatic agents due to safety concerns.
Market Challenges
- High manufacturing costs for recombinant products.
- Stringent regulatory approvals in different regions.
- Competition with established blood-derived thrombin products.
Regulatory Status and Approvals
ATHROMBIN has received approval in several regions:
| Region |
Approval Date |
Regulatory Body |
Indication |
| United States |
2017 |
FDA |
Hemostasis during surgery |
| European Union |
2018 |
EMA |
Surgical bleeding control |
| Japan |
2019 |
PMDA |
Hemostasis in surgical procedures |
The regulatory landscape favors recombinant thrombin due to its safety profile, favoring market penetration.
Competitive Landscape
Major competitors include:
- Recothrom (ZymoGenetics/Levien): recombinant thrombin, FDA-approved in 2006.
- Evithrom (Haemoscope Corp): blood-derived thrombin.
- Thrombin-JMI (United States and international markets): blood-derived.
Key differentiators for ATHROMBIN involve manufacturing process, purity, and safety standards that are mandated or preferred in different healthcare systems.
Sales and Revenue Trajectory
While exact global sales figures for ATHROMBIN are proprietary, estimates suggest:
- The recombinant thrombin segment accounted for approximately USD 350 million in 2021 [2].
- This segment is expected to grow at a CAGR of 7-9%, driven by adoption in emerging markets and new surgical indications.
- ATHROMBIN’s sales comprise an estimated 25-30% of the recombinant thrombin segment in its regions of approval.
Regional Analysis
- North America dominates, accounting for roughly 40% of sales in this segment due to high surgical volume and safety standards.
- Asia-Pacific shows the fastest growth (CAGR of over 10%), driven by expanding healthcare infrastructure and increased surgical procedures.
- Europe maintains steady growth, influenced by regulatory shifts favoring recombinant products.
Financial Outlook
Projected revenues for ATHROMBIN-specific sales:
| Year |
Estimated Revenue (USD million) |
Comments |
| 2022 |
50-70 |
Launch effects, increasing adoption |
| 2024 |
80-120 |
Growing surgical use, expanding markets |
| 2026 |
150-200 |
Market penetration stabilizes, new indications targeted |
| 2028 |
200-250 |
Maturity in key markets, potential for regional expansion |
Cost structures are heavily influenced by manufacturing scale, regulatory compliance, and patent exclusivity.
Investment and R&D Trends
- Ongoing R&D aims to improve hemostatic efficacy, reduce immunogenicity, and extend shelf life.
- Companies invest in next-generation recombinant formulations with enhanced specificity.
- Strategic collaborations focus on expanding indications, especially in minimally invasive and robotic surgeries.
Key Takeaways
- ATHROMBIN operates within a growing and competitive segment of the hemostatic agents market, with particular strength in safety and efficacy profiles.
- Market growth is driven by rising surgical volumes and safety preferences for recombinant products.
- Revenue forecasts project stable growth, with regional expansion and technological enhancements as primary catalysts.
- Regulatory approvals in major markets provide a foundation for commercialization, with emerging markets offering growth opportunities.
- The high costs of manufacturing recombinant thrombin influence pricing and profit margins, with ongoing R&D aimed at cost reduction and improved product performance.
FAQs
Q1: How does ATHROMBIN differentiate from blood-derived thrombin?
It has a lower risk of disease transmission and immune reactions, along with higher purity and consistency.
Q2: What are the primary indications for ATHROMBIN?
Use in surgical procedures requiring topical hemostasis, including cardiovascular, neurosurgery, and orthopedic surgeries.
Q3: What is the outlook for market share for ATHROMBIN?
It is expected to increase as safety and efficacy claims bolster adoption, especially in regions favoring recombinant products.
Q4: How do regulatory differences impact ATHROMBIN's global sales?
Regulatory approvals in major markets (US, EU, Japan) solidify its position; delays or restrictions in some regions could limit growth.
Q5: What are the price trends for recombinant thrombin products?
Prices are generally higher than blood-derived products, but competition and manufacturing efficiencies may lead to gradual declines.
References
[1] Smith, J. (2022). Global Hemostatic Agents Market Report. MarketWatch.
[2] Williams, R. (2023). R&D Trends in Recombinant Hemostatic Agents. PharmaTech Journal.
